ReviewAntibiotics (Basel, Switzerland)2020
Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections.
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Can phage-antibiotic combinations overcome uropathogenic Escherichia coli regrowth? evidence from in vitro and in vivo models.Virology journal · 2026Article
- Phage therapy for antimicrobial-resistant Klebsiella spp. infections: a review of mechanisms, synergies, and clinical potential.Archives of microbiology · 2025Review
- Isolation, identification, and genome analysis of the novel Escherichia coli phage XH12 and enhancement of the antibacterial activity of its lysozyme by chimeric cationic peptides.Archives of virology · 2025Article
- Endolysin EN572-5 as an alternative to treat urinary tract infection caused by Streptococcus agalactiae.Applied microbiology and biotechnology · 2024Article
- Does Phage Therapy Need a Pan-Phage?Pathogens (Basel, Switzerland) · 2024Review
- Engineered phage enzymes against drug-resistant pathogens: a review on advances and applications.Bioprocess and biosystems engineering · 2024Review
- Molecular Machinery of the Triad Holin, Endolysin, and Spanin: Key Players Orchestrating Bacteriophage-Induced Cell Lysis and their Therapeutic Applications.Protein and peptide letters · 2024Review
- Bacteriophage-mediated approaches for biofilm control.Frontiers in cellular and infection microbiology · 2024Review
- Two Newly IsolatedViruses · 2022Article
- How Good are Bacteriophages as an Alternative Therapy to Mitigate Biofilms of Nosocomial Infections.Infection and drug resistance · 2022Review
- Urinary Tract Virome as an Urgent Target for Metagenomics.Life (Basel, Switzerland) · 2021Review
- Genomic Analysis of Prophages fromMicroorganisms · 2021Article
- Engineered endolysin-based "artilysins" for controlling the gram-negative pathogen Helicobacter pylori.AMB Express · 2021Article
- Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review.Annals of clinical microbiology and antimicrobials · 2021Review
- The Role of Antibiotic ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Phage Prevalence in the Human Urinary Tract-Current Knowledge and Therapeutic Implications.Microorganisms · 2020Review
- Complete Genome Sequence of a Jumbo Bacteriophage, vB_pir03, against Vibrio harveyi.Microbiology resource announcements · 2020Article
- Phage Therapy, Lysin Therapy, and Antibiotics: A Trio Due to Come.Antibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections represent a major public health problem as the rapid emergence of antibiotic-resistant strains among uropathogens is causing the failure of many current treatments. The use of bacteriophages (phages) and their derivatives to combat infectious diseases is an old approach that has been forgotten by the West for a long time, mostly due to the discovery and great success of antibiotics. In the present so-called "post-antibiotic era", many researchers are turning their attention to the re-discovered phage therapy, as an effective alternative to antibiotics. Phage therapy includes the use of natural or engineered phages, as well as their purified lytic enzymes to destroy pathogenic strains. Many in vitro and in vivo studies have been conducted, and these have proved the great potential for this therapy against uropathogenic bacteria. Nevertheless, to date, the lack of appropriate clinical trials has hindered its widespread clinic application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.